Table 2 Baseline characteristics according to status of glucose metabolism
Variables | Total (N = 4594) | NGR (N = 801) | Pre-DM (N = 1904) | DM (N = 1889) | p value for trend |
|---|---|---|---|---|---|
Baseline characteristics | |||||
 Age (years) | 58.2 ± 9.9 | 55.2 ± 9.9 | 58.3 ± 9.5 | 59.3 ± 9.7 | < 0.001* |
 Male (n, %) | 3266 (71.9%) | 617 (77.0%) | 1346 (70.7%) | 1303 (69.0%) | < 0.001* |
 BMI (kg/m2) | 25.92 ± 3.14 | 25.51 ± 3.01 | 25.69 ± 2.96 | 26.38 ± 3.42 | 0.006 |
 Hypertension (n, %) | 3005 (65.4%) | 461 (57.6%) | 1200 (63.0%) | 1344 (71.1%) | < 0.001 |
 Dyslipidemia (n, %) | 4147 (90.3%) | 701 (87.5%) | 1745 (91.6%) | 1701 (90.0%) | 0.004* |
 Current smokers (n, %) | 1438 (31.3%) | 332 (41.4%) | 704 (37.0%) | 402 (21.3%) | < 0.001 |
 Peripheral vascular disease (n, %) | 59 (1.3%) | 6 (0.7%) | 18 (0.9%) | 35 (1.9%) | 0.015 |
 Cerebrovascular disease (n, %) | 145 (3.2%) | 24 (3.0%) | 60 (3.2%) | 61 (3.2%) | 0.951 |
 Family history of CAD (n, %) | 643 (14.0%) | 137 (17.1%) | 255 (13.4%) | 251 (13.3%) | 0.020* |
Laboratory data | |||||
 Triglyceride (mmol/L) | 1.80 ± 1.23 | 1.67 ± 1.14 | 1.73 ± 1.00 | 1.93 ± 1.46 | < 0.001 |
 TC (mmol/L) | 4.14 ± 1.17 | 4.03 ± 1.03 | 4.19 ± 1.17 | 4.14 ± 1.22 | < 0.001* |
 LDL-C (mmol/L) | 2.51 ± 0.99 | 2.45 ± 1.01 | 2.54 ± 0.97 | 2.50 ± 0.95 | 0.284 |
 HDL-C (mmol/L) | 1.05 ± 0.29 | 1.07 ± 0.31 | 1.08 ± 0.30 | 1.03 ± 0.28 | 0.001 |
 Glucose (mmol/L) | 6.20 ± 2.04 | 4.79 ± 0.42 | 5.32 ± 0.65 | 7.69 ± 2.41 | < 0.001* |
 HbA1c (%) | 6.54 ± 1.24 | 5.37 ± 0.24 | 5.05 ± 0.26 | 7.64 ± 1.23 | < 0.001* |
 H-FABP (ng/mL) | 2.45 ± 1.86 | 2.10 ± 1.13 | 2.41 ± 1.71 | 2.64 ± 2.21 | < 0.001* |
 Creatinine (μmol/L) | 77.97 ± 17.30 | 78.55 ± 16.28 | 78.40 ± 18.94 | 77.29 ± 15.95 | 0.532 |
 eGFR (mL/min/1.73 m2) | 93.74 ± 9.12 | 95.77 ± 8.87 | 93.80 ± 8.64 | 92.81 ± 9.56 | < 0.001* |
Treatments in hospital | |||||
 Aspirin (n, %) | 4462 (97.1%) | 776 (96.9%) | 1861 (97.7%) | 1825 (96.6%) | 0.103 |
 β-Blokers (n, %) | 3417 (78.3%) | 595 (74.3%) | 1466 (77.0%) | 1536 (81.3%) | < 0.001 |
 Lipid-lowering mediation (n, %) | 4269 (92.9%) | 731 (91.3%) | 1786 (93.8%) | 1752 (92.7%) | 0.058 |
 ACEI or ARB (n, %) | 2157 (47.0%) | 334 (41.7%) | 877 (46.1%) | 946 (50.1%) | < 0.001 |
 Gensini score | 34.50 ± 32.07 | 30.94 ± 28.02 | 32.16 ± 29.54 | 38.38 ± 35.56 | < 0.001 |
Events (n, %) | 380 (8.3%) | 45 (5.6%) | 125 (6.6%) | 210 (11.1%) | < 0.001 |